APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vasodilators for Heart Disease

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Vasodilators for Heart Disease Industry Growth and Trends Forecast to 2032

Report ID 173885130127 December 2025123 pages

Choose your research edition.

Industry ResearchVasodilators for Heart Disease Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Vasodilators for Heart Disease Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Vasodilators for Heart Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vasodilators for Heart Disease Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Vasodilators for Heart Disease Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global Vasodilators for Heart Disease market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Vasodilators for Heart Disease is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Vasodilators for Heart Disease is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vasodilators for Heart Disease is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vasodilators for Heart Disease include Chongqing Yaoyou Pharmaceutical Co., Ltd., Southwest Pharmaceutical Co., Ltd., Shanghai Hefeng Pharmaceutical Co., Ltd., Shanghai Aifa Pharmaceutical Co., Ltd., Shanxi Kangbao Biological Products Co., Ltd., Shandong New Era Pharmaceutical Co., Ltd., Shandong Fangming Pharmaceutical Group Co., Ltd., Sancai Shiqi Pharmaceutical Co., Ltd. and Lunan Beite Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Vasodilators for Heart Disease market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Vasodilators for Heart Disease market size, estimates, and forecasts are presented in terms of sales volume (Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Vasodilators for Heart Disease market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Vasodilators for Heart Disease.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Vasodilators for Heart Disease market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Vasodilators for Heart Disease Market by Company

Chongqing Yaoyou Pharmaceutical Co., Ltd.

Southwest Pharmaceutical Co., Ltd.

Shanghai Hefeng Pharmaceutical Co., Ltd.

Shanghai Aifa Pharmaceutical Co., Ltd.

Shanxi Kangbao Biological Products Co., Ltd.

Shandong New Era Pharmaceutical Co., Ltd.

Shandong Fangming Pharmaceutical Group Co., Ltd.

Sancai Shiqi Pharmaceutical Co., Ltd.

Lunan Beite Pharmaceutical Co., Ltd.

Jiangxi Haiersi Pharmaceutical Co., Ltd.

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Jiangsu Shenlong Pharmaceutical Co., Ltd.

Jiangsu Jiuxu Pharmaceutical Co., Ltd.

Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.

Hulunbeier Songlu Pharmaceutical Co., Ltd.

Henan Runhong Pharmaceutical Co., Ltd.

Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.

Chenxin Pharmaceutical Co., Ltd.

Beijing Yimin Pharmaceutical Co., Ltd.

Beijing Hengsheng Pharmaceutical Co., Ltd.

Anhui Fengyuan Pharmaceutical Co., Ltd.

TORRENT PHARMA INC.

Sanofi

Pfizer

Matins Pharma

Copperhead Chemical Company

Axplora

Aditya Chemicals

Vasodilators for Heart Disease Segment by Type

Isosorbide Mononitrate

Nicorandil

Nitroglycerin

Isosorbide Dinitrate

Vasodilators for Heart Disease Segment by Application

Clinic

Hospital

Other

Vasodilators for Heart Disease Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vasodilators for Heart Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vasodilators for Heart Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vasodilators for Heart Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vasodilators for Heart Disease manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Vasodilators for Heart Disease in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Isosorbide Mononitrate Table 2. Major Company of Nicorandil Table 3. Major Company of Nitroglycerin Table 4. Major Company of Isosorbide Dinitrate Table 5. Global Vasodilators for Heart Disease Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Vasodilators for Heart Disease Sales by Type (2021-2026) & (Units) Table 7. Global Vasodilators for Heart Disease Sales Market Share in Volume by Type (2021-2026) Table 8. Global Vasodilators for Heart Disease Sales by Type (2021-2026) & (US$ Million) Table 9. Global Vasodilators for Heart Disease Sales Market Share in Value by Type (2021-2026) Table 10. Global Vasodilators for Heart Disease Price by Type (2021-2026) & (US$/Unit) Table 11. Global Vasodilators for Heart Disease Sales by Type (2027-2032) & (Units) Table 12. Global Vasodilators for Heart Disease Sales Market Share in Volume by Type (2027-2032) Table 13. Global Vasodilators for Heart Disease Sales by Type (2027-2032) & (US$ Million) Table 14. Global Vasodilators for Heart Disease Sales Market Share in Value by Type (2027-2032) Table 15. Global Vasodilators for Heart Disease Price by Type (2027-2032) & (US$/Unit) Table 16. North America Vasodilators for Heart Disease Sales by Type (2021-2026) & (Units) Table 17. North America Vasodilators for Heart Disease Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Vasodilators for Heart Disease Sales by Type (2021-2026) & (Units) Table 19. Europe Vasodilators for Heart Disease Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Vasodilators for Heart Disease Sales by Type (2021-2026) & (Units) Table 21. Asia-Pacific Vasodilators for Heart Disease Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Vasodilators for Heart Disease Sales by Type (2021-2026) & (Units) Table 23. Latin America Vasodilators for Heart Disease Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Vasodilators for Heart Disease Sales by Type (2021-2026) & (Units) Table 25. Middle East and Africa Vasodilators for Heart Disease Sales by Type (2021-2026) & (US$ Million) Table 26. Vasodilators for Heart Disease Industry Trends Table 27. Vasodilators for Heart Disease Industry Drivers Table 28. Vasodilators for Heart Disease Industry Opportunities and Challenges Table 29. Vasodilators for Heart Disease Industry Restraints Table 30. Global Vasodilators for Heart Disease Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Vasodilators for Heart Disease Revenue Market Share by Company (2021-2026) Table 32. Global Vasodilators for Heart Disease Sales by Company (2021-2026) & (Units) Table 33. Global Vasodilators for Heart Disease Sales Share by Company (2021-2026) Table 34. Global Vasodilators for Heart Disease Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Vasodilators for Heart Disease Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Vasodilators for Heart Disease Major Company Production Sites and Headquarters Table 37. Global Vasodilators for Heart Disease Company, Product Type & Application Table 38. Global Vasodilators for Heart Disease Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Vasodilators for Heart Disease by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Vasodilators for Heart Disease Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Vasodilators for Heart Disease Sales by Region (2021-2026) & (Units) Table 43. Global Vasodilators for Heart Disease Sales Market Share in Volume by Region (2021-2026) Table 44. Global Vasodilators for Heart Disease Sales by Region (2021-2026) & (US$ Million) Table 45. Global Vasodilators for Heart Disease Sales Market Share in Value by Region (2021-2026) Table 46. Global Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Vasodilators for Heart Disease Sales by Region (2027-2032) & (Units) Table 48. Global Vasodilators for Heart Disease Sales Market Share in Volume by Region (2027-2032) Table 49. Global Vasodilators for Heart Disease Sales by Region (2027-2032) & (US$ Million) Table 50. Global Vasodilators for Heart Disease Sales Market Share in Value by Region (2027-2032) Table 51. Global Vasodilators for Heart Disease Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Vasodilators for Heart Disease Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Vasodilators for Heart Disease Sales by Application (2021-2026) & (Units) Table 54. Global Vasodilators for Heart Disease Sales Market Share in Volume by Application (2021-2026) Table 55. Global Vasodilators for Heart Disease Sales by Application (2021-2026) & (US$ Million) Table 56. Global Vasodilators for Heart Disease Sales Market Share in Value by Application (2021-2026) Table 57. Global Vasodilators for Heart Disease Price by Application (2021-2026) & (US$/Unit) Table 58. Global Vasodilators for Heart Disease Sales by Application (2027-2032) & (Units) Table 59. Global Vasodilators for Heart Disease Sales Market Share in Volume by Application (2027-2032) Table 60. Global Vasodilators for Heart Disease Sales by Application (2027-2032) & (US$ Million) Table 61. Global Vasodilators for Heart Disease Sales Market Share in Value by Application (2027-2032) Table 62. Global Vasodilators for Heart Disease Price by Application (2027-2032) & (US$/Unit) Table 63. North America Vasodilators for Heart Disease Sales by Application (2021-2026) & (Units) Table 64. North America Vasodilators for Heart Disease Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Vasodilators for Heart Disease Sales by Application (2021-2026) & (Units) Table 66. Europe Vasodilators for Heart Disease Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Vasodilators for Heart Disease Sales by Application (2021-2026) & (Units) Table 68. Asia-Pacific Vasodilators for Heart Disease Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Vasodilators for Heart Disease Sales by Application (2021-2026) & (Units) Table 70. Latin America Vasodilators for Heart Disease Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Vasodilators for Heart Disease Sales by Application (2021-2026) & (Units) Table 72. Middle East and Africa Vasodilators for Heart Disease Sales by Application (2021-2026) & (US$ Million) Table 73. Chongqing Yaoyou Pharmaceutical Co., Ltd. Company Information Table 74. Chongqing Yaoyou Pharmaceutical Co., Ltd. Business Overview Table 75. Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 77. Chongqing Yaoyou Pharmaceutical Co., Ltd. Recent Development Table 78. Southwest Pharmaceutical Co., Ltd. Company Information Table 79. Southwest Pharmaceutical Co., Ltd. Business Overview Table 80. Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 82. Southwest Pharmaceutical Co., Ltd. Recent Development Table 83. Shanghai Hefeng Pharmaceutical Co., Ltd. Company Information Table 84. Shanghai Hefeng Pharmaceutical Co., Ltd. Business Overview Table 85. Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 87. Shanghai Hefeng Pharmaceutical Co., Ltd. Recent Development Table 88. Shanghai Aifa Pharmaceutical Co., Ltd. Company Information Table 89. Shanghai Aifa Pharmaceutical Co., Ltd. Business Overview Table 90. Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 92. Shanghai Aifa Pharmaceutical Co., Ltd. Recent Development Table 93. Shanxi Kangbao Biological Products Co., Ltd. Company Information Table 94. Shanxi Kangbao Biological Products Co., Ltd. Business Overview Table 95. Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 97. Shanxi Kangbao Biological Products Co., Ltd. Recent Development Table 98. Shandong New Era Pharmaceutical Co., Ltd. Company Information Table 99. Shandong New Era Pharmaceutical Co., Ltd. Business Overview Table 100. Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 102. Shandong New Era Pharmaceutical Co., Ltd. Recent Development Table 103. Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information Table 104. Shandong Fangming Pharmaceutical Group Co., Ltd. Business Overview Table 105. Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 107. Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Development Table 108. Sancai Shiqi Pharmaceutical Co., Ltd. Company Information Table 109. Sancai Shiqi Pharmaceutical Co., Ltd. Business Overview Table 110. Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 112. Sancai Shiqi Pharmaceutical Co., Ltd. Recent Development Table 113. Lunan Beite Pharmaceutical Co., Ltd. Company Information Table 114. Lunan Beite Pharmaceutical Co., Ltd. Business Overview Table 115. Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 117. Lunan Beite Pharmaceutical Co., Ltd. Recent Development Table 118. Jiangxi Haiersi Pharmaceutical Co., Ltd. Company Information Table 119. Jiangxi Haiersi Pharmaceutical Co., Ltd. Business Overview Table 120. Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 122. Jiangxi Haiersi Pharmaceutical Co., Ltd. Recent Development Table 123. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information Table 124. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview Table 125. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 127. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Development Table 128. Jiangsu Shenlong Pharmaceutical Co., Ltd. Company Information Table 129. Jiangsu Shenlong Pharmaceutical Co., Ltd. Business Overview Table 130. Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 132. Jiangsu Shenlong Pharmaceutical Co., Ltd. Recent Development Table 133. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Company Information Table 134. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Business Overview Table 135. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 137. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Recent Development Table 138. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Company Information Table 139. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Business Overview Table 140. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 142. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Recent Development Table 143. Hulunbeier Songlu Pharmaceutical Co., Ltd. Company Information Table 144. Hulunbeier Songlu Pharmaceutical Co., Ltd. Business Overview Table 145. Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 147. Hulunbeier Songlu Pharmaceutical Co., Ltd. Recent Development Table 148. Henan Runhong Pharmaceutical Co., Ltd. Company Information Table 149. Henan Runhong Pharmaceutical Co., Ltd. Business Overview Table 150. Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 152. Henan Runhong Pharmaceutical Co., Ltd. Recent Development Table 153. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Company Information Table 154. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Business Overview Table 155. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 157. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Recent Development Table 158. Chenxin Pharmaceutical Co., Ltd. Company Information Table 159. Chenxin Pharmaceutical Co., Ltd. Business Overview Table 160. Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 161. Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 162. Chenxin Pharmaceutical Co., Ltd. Recent Development Table 163. Beijing Yimin Pharmaceutical Co., Ltd. Company Information Table 164. Beijing Yimin Pharmaceutical Co., Ltd. Business Overview Table 165. Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 166. Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 167. Beijing Yimin Pharmaceutical Co., Ltd. Recent Development Table 168. Beijing Hengsheng Pharmaceutical Co., Ltd. Company Information Table 169. Beijing Hengsheng Pharmaceutical Co., Ltd. Business Overview Table 170. Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 171. Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 172. Beijing Hengsheng Pharmaceutical Co., Ltd. Recent Development Table 173. Anhui Fengyuan Pharmaceutical Co., Ltd. Company Information Table 174. Anhui Fengyuan Pharmaceutical Co., Ltd. Business Overview Table 175. Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 176. Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio Table 177. Anhui Fengyuan Pharmaceutical Co., Ltd. Recent Development Table 178. TORRENT PHARMA INC. Company Information Table 179. TORRENT PHARMA INC. Business Overview Table 180. TORRENT PHARMA INC. Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 181. TORRENT PHARMA INC. Vasodilators for Heart Disease Product Portfolio Table 182. TORRENT PHARMA INC. Recent Development Table 183. Sanofi Company Information Table 184. Sanofi Business Overview Table 185. Sanofi Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 186. Sanofi Vasodilators for Heart Disease Product Portfolio Table 187. Sanofi Recent Development Table 188. Pfizer Company Information Table 189. Pfizer Business Overview Table 190. Pfizer Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 191. Pfizer Vasodilators for Heart Disease Product Portfolio Table 192. Pfizer Recent Development Table 193. Matins Pharma Company Information Table 194. Matins Pharma Business Overview Table 195. Matins Pharma Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 196. Matins Pharma Vasodilators for Heart Disease Product Portfolio Table 197. Matins Pharma Recent Development Table 198. Copperhead Chemical Company Company Information Table 199. Copperhead Chemical Company Business Overview Table 200. Copperhead Chemical Company Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 201. Copperhead Chemical Company Vasodilators for Heart Disease Product Portfolio Table 202. Copperhead Chemical Company Recent Development Table 203. Axplora Company Information Table 204. Axplora Business Overview Table 205. Axplora Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 206. Axplora Vasodilators for Heart Disease Product Portfolio Table 207. Axplora Recent Development Table 208. Aditya Chemicals Company Information Table 209. Aditya Chemicals Business Overview Table 210. Aditya Chemicals Vasodilators for Heart Disease Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 211. Aditya Chemicals Vasodilators for Heart Disease Product Portfolio Table 212. Aditya Chemicals Recent Development Table 213. North America Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 214. North America Vasodilators for Heart Disease Sales by Country (2021-2026) & (Units) Table 215. North America Vasodilators for Heart Disease Sales Market Share by Country (2021-2026) Table 216. North America Vasodilators for Heart Disease Sales Forecast by Country (2027-2032) & (Units) Table 217. North America Vasodilators for Heart Disease Sales Market Share Forecast by Country (2027-2032) Table 218. North America Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 219. North America Vasodilators for Heart Disease Market Size by Country (2021-2026) & (US$ Million) Table 220. North America Vasodilators for Heart Disease Market Share by Country (2021-2026) Table 221. North America Vasodilators for Heart Disease Market Size Forecast by Country (2027-2032) & (US$ Million) Table 222. North America Vasodilators for Heart Disease Market Share Forecast by Country (2027-2032) Table 223. Europe Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 224. Europe Vasodilators for Heart Disease Sales by Country (2021-2026) & (Units) Table 225. Europe Vasodilators for Heart Disease Sales Market Share by Country (2021-2026) Table 226. Europe Vasodilators for Heart Disease Sales Forecast by Country (2027-2032) & (Units) Table 227. Europe Vasodilators for Heart Disease Sales Market Share Forecast by Country (2027-2032) Table 228. Europe Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 229. Europe Vasodilators for Heart Disease Market Size by Country (2021-2026) & (US$ Million) Table 230. Europe Vasodilators for Heart Disease Market Share by Country (2021-2026) Table 231. Europe Vasodilators for Heart Disease Market Size Forecast by Country (2027-2032) & (US$ Million) Table 232. Europe Vasodilators for Heart Disease Market Share Forecast by Country (2027-2032) Table 233. Asia-Pacific Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 234. Asia-Pacific Vasodilators for Heart Disease Sales by Country (2021-2026) & (Units) Table 235. Asia-Pacific Vasodilators for Heart Disease Sales Market Share by Country (2021-2026) Table 236. Asia-Pacific Vasodilators for Heart Disease Sales Forecast by Country (2027-2032) & (Units) Table 237. Asia-Pacific Vasodilators for Heart Disease Sales Market Share Forecast by Country (2027-2032) Table 238. Asia-Pacific Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 239. Asia-Pacific Vasodilators for Heart Disease Market Size by Country (2021-2026) & (US$ Million) Table 240. Asia-Pacific Vasodilators for Heart Disease Market Share by Country (2021-2026) Table 241. Asia-Pacific Vasodilators for Heart Disease Market Size Forecast by Country (2027-2032) & (US$ Million) Table 242. Asia-Pacific Vasodilators for Heart Disease Market Share Forecast by Country (2027-2032) Table 243. Latin America Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 244. Latin America Vasodilators for Heart Disease Sales by Country (2021-2026) & (Units) Table 245. Latin America Vasodilators for Heart Disease Sales Market Share by Country (2021-2026) Table 246. Latin America Vasodilators for Heart Disease Sales Forecast by Country (2027-2032) & (Units) Table 247. Latin America Vasodilators for Heart Disease Sales Market Share Forecast by Country (2027-2032) Table 248. Latin America Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 249. Latin America Vasodilators for Heart Disease Market Size by Country (2021-2026) & (US$ Million) Table 250. Latin America Vasodilators for Heart Disease Market Share by Country (2021-2026) Table 251. Latin America Vasodilators for Heart Disease Market Size Forecast by Country (2027-2032) & (US$ Million) Table 252. Latin America Vasodilators for Heart Disease Market Share Forecast by Country (2027-2032) Table 253. Middle East and Africa Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 254. Middle East and Africa Vasodilators for Heart Disease Sales by Country (2021-2026) & (Units) Table 255. Middle East and Africa Vasodilators for Heart Disease Sales Market Share by Country (2021-2026) Table 256. Middle East and Africa Vasodilators for Heart Disease Sales Forecast by Country (2027-2032) & (Units) Table 257. Middle East and Africa Vasodilators for Heart Disease Sales Market Share Forecast by Country (2027-2032) Table 258. Middle East and Africa Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 259. Middle East and Africa Vasodilators for Heart Disease Market Size by Country (2021-2026) & (US$ Million) Table 260. Middle East and Africa Vasodilators for Heart Disease Market Share by Country (2021-2026) Table 261. Middle East and Africa Vasodilators for Heart Disease Market Size Forecast by Country (2027-2032) & (US$ Million) Table 262. Middle East and Africa Vasodilators for Heart Disease Market Share Forecast by Country (2027-2032) Table 263. Key Raw Materials Table 264. Raw Materials Key Suppliers Table 265. Vasodilators for Heart Disease Distributors List Table 266. Vasodilators for Heart Disease Customers List Table 267. Research Programs/Design for This Report Table 268. Authors List of This Report Table 269. Secondary Sources Table 270. Primary Sources List of Figures Figure 1. Vasodilators for Heart Disease Image Figure 2. Global Vasodilators for Heart Disease Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vasodilators for Heart Disease Market Size (2021-2032) & (US$ Million) Figure 4. Global Vasodilators for Heart Disease Sales (2021-2032) & (Units) Figure 5. Isosorbide Mononitrate Image Figure 6. Global Isosorbide Mononitrate Sales YoY Growth (2021-2032) & (Units) Figure 7. Nicorandil Image Figure 8. Global Nicorandil Sales YoY Growth (2021-2032) & (Units) Figure 9. Nitroglycerin Image Figure 10. Global Nitroglycerin Sales YoY Growth (2021-2032) & (Units) Figure 11. Isosorbide Dinitrate Image Figure 12. Global Isosorbide Dinitrate Sales YoY Growth (2021-2032) & (Units) Figure 13. Global Vasodilators for Heart Disease Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Vasodilators for Heart Disease Market Share by Type 2025 VS 2032 Figure 15. North America Vasodilators for Heart Disease Sales Market Share in Volume by Type in 2025 Figure 16. North America Vasodilators for Heart Disease Sales Market Share in Value by Type in 2025 Figure 17. Europe Vasodilators for Heart Disease Sales Market Share in Volume by Type in 2025 Figure 18. Europe Vasodilators for Heart Disease Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Vasodilators for Heart Disease Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Vasodilators for Heart Disease Sales Market Share in Value by Type in 2025 Figure 21. Latin America Vasodilators for Heart Disease Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Vasodilators for Heart Disease Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Vasodilators for Heart Disease Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Vasodilators for Heart Disease Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Vasodilators for Heart Disease Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Clinic Image Figure 28. Global Clinic Sales YoY Growth (2021-2032) & (Units) Figure 29. Hospital Image Figure 30. Global Hospital Sales YoY Growth (2021-2032) & (Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (Units) Figure 33. Global Vasodilators for Heart Disease Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Vasodilators for Heart Disease Market Share by Application 2025 VS 2032 Figure 35. North America Vasodilators for Heart Disease Sales Market Share in Volume by Application in 2025 Figure 36. North America Vasodilators for Heart Disease Sales Market Share in Value by Application in 2025 Figure 37. Europe Vasodilators for Heart Disease Sales Market Share in Volume by Application in 2025 Figure 38. Europe Vasodilators for Heart Disease Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Vasodilators for Heart Disease Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Vasodilators for Heart Disease Sales Market Share in Value by Application in 2025 Figure 41. Latin America Vasodilators for Heart Disease Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Vasodilators for Heart Disease Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Vasodilators for Heart Disease Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Vasodilators for Heart Disease Sales Market Share in Value by Application in 2025 Figure 45. North America Vasodilators for Heart Disease Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 46. North America Vasodilators for Heart Disease Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Vasodilators for Heart Disease Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Vasodilators for Heart Disease Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Vasodilators for Heart Disease Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 50. Europe Vasodilators for Heart Disease Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Vasodilators for Heart Disease Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Vasodilators for Heart Disease Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Vasodilators for Heart Disease Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 54. Asia-Pacific Vasodilators for Heart Disease Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Vasodilators for Heart Disease Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Vasodilators for Heart Disease Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Vasodilators for Heart Disease Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 58. Latin America Vasodilators for Heart Disease Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Vasodilators for Heart Disease Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Vasodilators for Heart Disease Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Vasodilators for Heart Disease Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 62. Middle East and Africa Vasodilators for Heart Disease Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Vasodilators for Heart Disease Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Vasodilators for Heart Disease Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Vasodilators for Heart Disease Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Vasodilators for Heart Disease Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Y

Scope & coverage.

Types
  • Isosorbide Mononitrate
  • Nicorandil
  • Nitroglycerin
  • Isosorbide Dinitrate
Applications
  • Clinic
  • Hospital
  • Other
Companies covered
  • Chongqing Yaoyou Pharmaceutical Co., Ltd.
  • Southwest Pharmaceutical Co., Ltd.
  • Shanghai Hefeng Pharmaceutical Co., Ltd.
  • Shanghai Aifa Pharmaceutical Co., Ltd.
  • Shanxi Kangbao Biological Products Co., Ltd.
  • Shandong New Era Pharmaceutical Co., Ltd.
  • Shandong Fangming Pharmaceutical Group Co., Ltd.
  • Sancai Shiqi Pharmaceutical Co., Ltd.
  • Lunan Beite Pharmaceutical Co., Ltd.
  • Jiangxi Haiersi Pharmaceutical Co., Ltd.
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  • Jiangsu Shenlong Pharmaceutical Co., Ltd.
  • Jiangsu Jiuxu Pharmaceutical Co., Ltd.
  • Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.
  • Hulunbeier Songlu Pharmaceutical Co., Ltd.
  • Henan Runhong Pharmaceutical Co., Ltd.
  • Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.
  • Chenxin Pharmaceutical Co., Ltd.
  • Beijing Yimin Pharmaceutical Co., Ltd.
  • Beijing Hengsheng Pharmaceutical Co., Ltd.
  • Anhui Fengyuan Pharmaceutical Co., Ltd.
  • TORRENT PHARMA INC.
  • Sanofi
  • Pfizer
  • Matins Pharma
  • Copperhead Chemical Company
  • Axplora
  • Aditya Chemicals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vasodilators for Heart Disease Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Vasodilators for Heart Disease Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Vasodilators for Heart Disease Market by Type
  6. 1.3.1 Isosorbide Mononitrate
  7. 1.3.2 Nicorandil
  8. 1.3.3 Nitroglycerin
  9. 1.3.4 Isosorbide Dinitrate
  10. 1.4 Global Vasodilators for Heart Disease Market Size by Type
  11. 1.4.1 Global Vasodilators for Heart Disease Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Vasodilators for Heart Disease Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Vasodilators for Heart Disease Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Vasodilators for Heart Disease Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Vasodilators for Heart Disease Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Vasodilators for Heart Disease Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Vasodilators for Heart Disease Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Vasodilators for Heart Disease Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Vasodilators for Heart Disease Industry Trends
  2. 2.2 Vasodilators for Heart Disease Industry Drivers
  3. 2.3 Vasodilators for Heart Disease Industry Opportunities and Challenges
  4. 2.4 Vasodilators for Heart Disease Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Vasodilators for Heart Disease Revenue (2021-2026)
  2. 3.2 Global Top Players by Vasodilators for Heart Disease Sales (2021-2026)
  3. 3.3 Global Top Players by Vasodilators for Heart Disease Price (2021-2026)
  4. 3.4 Global Vasodilators for Heart Disease Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vasodilators for Heart Disease Major Company Production Sites & Headquarters
  6. 3.6 Global Vasodilators for Heart Disease Company, Product Type & Application
  7. 3.7 Global Vasodilators for Heart Disease Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vasodilators for Heart Disease Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vasodilators for Heart Disease Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vasodilators for Heart Disease Tier 1, Tier 2, and Tier 3
4 Vasodilators for Heart Disease Regional Status and Outlook
  1. 4.1 Global Vasodilators for Heart Disease Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Vasodilators for Heart Disease Historic Market Size by Region
  3. 4.2.1 Global Vasodilators for Heart Disease Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Vasodilators for Heart Disease Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Vasodilators for Heart Disease Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Vasodilators for Heart Disease Forecasted Market Size by Region
  7. 4.3.1 Global Vasodilators for Heart Disease Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Vasodilators for Heart Disease Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Vasodilators for Heart Disease Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Vasodilators for Heart Disease by Application
  1. 5.1 Vasodilators for Heart Disease Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Other
  5. 5.2 Global Vasodilators for Heart Disease Market Size by Application
  6. 5.2.1 Global Vasodilators for Heart Disease Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Vasodilators for Heart Disease Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Vasodilators for Heart Disease Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Vasodilators for Heart Disease Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Vasodilators for Heart Disease Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Vasodilators for Heart Disease Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Vasodilators for Heart Disease Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Vasodilators for Heart Disease Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chongqing Yaoyou Pharmaceutical Co., Ltd.
  2. 6.1.1 Chongqing Yaoyou Pharmaceutical Co., Ltd. Company Information
  3. 6.1.2 Chongqing Yaoyou Pharmaceutical Co., Ltd. Business Overview
  4. 6.1.3 Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  6. 6.1.5 Chongqing Yaoyou Pharmaceutical Co., Ltd. Recent Developments
  7. 6.2 Southwest Pharmaceutical Co., Ltd.
  8. 6.2.1 Southwest Pharmaceutical Co., Ltd. Company Information
  9. 6.2.2 Southwest Pharmaceutical Co., Ltd. Business Overview
  10. 6.2.3 Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  12. 6.2.5 Southwest Pharmaceutical Co., Ltd. Recent Developments
  13. 6.3 Shanghai Hefeng Pharmaceutical Co., Ltd.
  14. 6.3.1 Shanghai Hefeng Pharmaceutical Co., Ltd. Company Information
  15. 6.3.2 Shanghai Hefeng Pharmaceutical Co., Ltd. Business Overview
  16. 6.3.3 Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  18. 6.3.5 Shanghai Hefeng Pharmaceutical Co., Ltd. Recent Developments
  19. 6.4 Shanghai Aifa Pharmaceutical Co., Ltd.
  20. 6.4.1 Shanghai Aifa Pharmaceutical Co., Ltd. Company Information
  21. 6.4.2 Shanghai Aifa Pharmaceutical Co., Ltd. Business Overview
  22. 6.4.3 Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  24. 6.4.5 Shanghai Aifa Pharmaceutical Co., Ltd. Recent Developments
  25. 6.5 Shanxi Kangbao Biological Products Co., Ltd.
  26. 6.5.1 Shanxi Kangbao Biological Products Co., Ltd. Company Information
  27. 6.5.2 Shanxi Kangbao Biological Products Co., Ltd. Business Overview
  28. 6.5.3 Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  30. 6.5.5 Shanxi Kangbao Biological Products Co., Ltd. Recent Developments
  31. 6.6 Shandong New Era Pharmaceutical Co., Ltd.
  32. 6.6.1 Shandong New Era Pharmaceutical Co., Ltd. Company Information
  33. 6.6.2 Shandong New Era Pharmaceutical Co., Ltd. Business Overview
  34. 6.6.3 Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  36. 6.6.5 Shandong New Era Pharmaceutical Co., Ltd. Recent Developments
  37. 6.7 Shandong Fangming Pharmaceutical Group Co., Ltd.
  38. 6.7.1 Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information
  39. 6.7.2 Shandong Fangming Pharmaceutical Group Co., Ltd. Business Overview
  40. 6.7.3 Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  42. 6.7.5 Shandong Fangming Pharmaceutical Group Co., Ltd. Recent Developments
  43. 6.8 Sancai Shiqi Pharmaceutical Co., Ltd.
  44. 6.8.1 Sancai Shiqi Pharmaceutical Co., Ltd. Company Information
  45. 6.8.2 Sancai Shiqi Pharmaceutical Co., Ltd. Business Overview
  46. 6.8.3 Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  48. 6.8.5 Sancai Shiqi Pharmaceutical Co., Ltd. Recent Developments
  49. 6.9 Lunan Beite Pharmaceutical Co., Ltd.
  50. 6.9.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information
  51. 6.9.2 Lunan Beite Pharmaceutical Co., Ltd. Business Overview
  52. 6.9.3 Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  54. 6.9.5 Lunan Beite Pharmaceutical Co., Ltd. Recent Developments
  55. 6.10 Jiangxi Haiersi Pharmaceutical Co., Ltd.
  56. 6.10.1 Jiangxi Haiersi Pharmaceutical Co., Ltd. Company Information
  57. 6.10.2 Jiangxi Haiersi Pharmaceutical Co., Ltd. Business Overview
  58. 6.10.3 Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  60. 6.10.5 Jiangxi Haiersi Pharmaceutical Co., Ltd. Recent Developments
  61. 6.11 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  62. 6.11.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information
  63. 6.11.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview
  64. 6.11.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  66. 6.11.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
  67. 6.12 Jiangsu Shenlong Pharmaceutical Co., Ltd.
  68. 6.12.1 Jiangsu Shenlong Pharmaceutical Co., Ltd. Company Information
  69. 6.12.2 Jiangsu Shenlong Pharmaceutical Co., Ltd. Business Overview
  70. 6.12.3 Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  72. 6.12.5 Jiangsu Shenlong Pharmaceutical Co., Ltd. Recent Developments
  73. 6.13 Jiangsu Jiuxu Pharmaceutical Co., Ltd.
  74. 6.13.1 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Company Information
  75. 6.13.2 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Business Overview
  76. 6.13.3 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  78. 6.13.5 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Recent Developments
  79. 6.14 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.
  80. 6.14.1 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Company Information
  81. 6.14.2 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Business Overview
  82. 6.14.3 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  84. 6.14.5 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Recent Developments
  85. 6.15 Hulunbeier Songlu Pharmaceutical Co., Ltd.
  86. 6.15.1 Hulunbeier Songlu Pharmaceutical Co., Ltd. Company Information
  87. 6.15.2 Hulunbeier Songlu Pharmaceutical Co., Ltd. Business Overview
  88. 6.15.3 Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  90. 6.15.5 Hulunbeier Songlu Pharmaceutical Co., Ltd. Recent Developments
  91. 6.16 Henan Runhong Pharmaceutical Co., Ltd.
  92. 6.16.1 Henan Runhong Pharmaceutical Co., Ltd. Company Information
  93. 6.16.2 Henan Runhong Pharmaceutical Co., Ltd. Business Overview
  94. 6.16.3 Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  96. 6.16.5 Henan Runhong Pharmaceutical Co., Ltd. Recent Developments
  97. 6.17 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.
  98. 6.17.1 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Company Information
  99. 6.17.2 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Business Overview
  100. 6.17.3 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  102. 6.17.5 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Recent Developments
  103. 6.18 Chenxin Pharmaceutical Co., Ltd.
  104. 6.18.1 Chenxin Pharmaceutical Co., Ltd. Company Information
  105. 6.18.2 Chenxin Pharmaceutical Co., Ltd. Business Overview
  106. 6.18.3 Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  108. 6.18.5 Chenxin Pharmaceutical Co., Ltd. Recent Developments
  109. 6.19 Beijing Yimin Pharmaceutical Co., Ltd.
  110. 6.19.1 Beijing Yimin Pharmaceutical Co., Ltd. Company Information
  111. 6.19.2 Beijing Yimin Pharmaceutical Co., Ltd. Business Overview
  112. 6.19.3 Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  114. 6.19.5 Beijing Yimin Pharmaceutical Co., Ltd. Recent Developments
  115. 6.20 Beijing Hengsheng Pharmaceutical Co., Ltd.
  116. 6.20.1 Beijing Hengsheng Pharmaceutical Co., Ltd. Company Information
  117. 6.20.2 Beijing Hengsheng Pharmaceutical Co., Ltd. Business Overview
  118. 6.20.3 Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  120. 6.20.5 Beijing Hengsheng Pharmaceutical Co., Ltd. Recent Developments
  121. 6.21 Anhui Fengyuan Pharmaceutical Co., Ltd.
  122. 6.21.1 Anhui Fengyuan Pharmaceutical Co., Ltd. Company Information
  123. 6.21.2 Anhui Fengyuan Pharmaceutical Co., Ltd. Business Overview
  124. 6.21.3 Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolio
  126. 6.21.5 Anhui Fengyuan Pharmaceutical Co., Ltd. Recent Developments
  127. 6.22 TORRENT PHARMA INC.
  128. 6.22.1 TORRENT PHARMA INC. Company Information
  129. 6.22.2 TORRENT PHARMA INC. Business Overview
  130. 6.22.3 TORRENT PHARMA INC. Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 TORRENT PHARMA INC. Vasodilators for Heart Disease Product Portfolio
  132. 6.22.5 TORRENT PHARMA INC. Recent Developments
  133. 6.23 Sanofi
  134. 6.23.1 Sanofi Company Information
  135. 6.23.2 Sanofi Business Overview
  136. 6.23.3 Sanofi Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Sanofi Vasodilators for Heart Disease Product Portfolio
  138. 6.23.5 Sanofi Recent Developments
  139. 6.24 Pfizer
  140. 6.24.1 Pfizer Company Information
  141. 6.24.2 Pfizer Business Overview
  142. 6.24.3 Pfizer Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Pfizer Vasodilators for Heart Disease Product Portfolio
  144. 6.24.5 Pfizer Recent Developments
  145. 6.25 Matins Pharma
  146. 6.25.1 Matins Pharma Company Information
  147. 6.25.2 Matins Pharma Business Overview
  148. 6.25.3 Matins Pharma Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Matins Pharma Vasodilators for Heart Disease Product Portfolio
  150. 6.25.5 Matins Pharma Recent Developments
  151. 6.26 Copperhead Chemical Company
  152. 6.26.1 Copperhead Chemical Company Company Information
  153. 6.26.2 Copperhead Chemical Company Business Overview
  154. 6.26.3 Copperhead Chemical Company Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Copperhead Chemical Company Vasodilators for Heart Disease Product Portfolio
  156. 6.26.5 Copperhead Chemical Company Recent Developments
  157. 6.27 Axplora
  158. 6.27.1 Axplora Company Information
  159. 6.27.2 Axplora Business Overview
  160. 6.27.3 Axplora Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  161. 6.27.4 Axplora Vasodilators for Heart Disease Product Portfolio
  162. 6.27.5 Axplora Recent Developments
  163. 6.28 Aditya Chemicals
  164. 6.28.1 Aditya Chemicals Company Information
  165. 6.28.2 Aditya Chemicals Business Overview
  166. 6.28.3 Aditya Chemicals Vasodilators for Heart Disease Sales, Revenue and Gross Margin (2021-2026)
  167. 6.28.4 Aditya Chemicals Vasodilators for Heart Disease Product Portfolio
  168. 6.28.5 Aditya Chemicals Recent Developments
7 North America by Country
  1. 7.1 North America Vasodilators for Heart Disease Sales by Country
  2. 7.1.1 North America Vasodilators for Heart Disease Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Vasodilators for Heart Disease Sales by Country (2021-2026)
  4. 7.1.3 North America Vasodilators for Heart Disease Sales Forecast by Country (2027-2032)
  5. 7.2 North America Vasodilators for Heart Disease Market Size by Country
  6. 7.2.1 North America Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Vasodilators for Heart Disease Market Size by Country (2021-2026)
  8. 7.2.3 North America Vasodilators for Heart Disease Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Vasodilators for Heart Disease Sales by Country
  2. 8.1.1 Europe Vasodilators for Heart Disease Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Vasodilators for Heart Disease Sales by Country (2021-2026)
  4. 8.1.3 Europe Vasodilators for Heart Disease Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Vasodilators for Heart Disease Market Size by Country
  6. 8.2.1 Europe Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Vasodilators for Heart Disease Market Size by Country (2021-2026)
  8. 8.2.3 Europe Vasodilators for Heart Disease Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Vasodilators for Heart Disease Sales by Country
  2. 9.1.1 Asia-Pacific Vasodilators for Heart Disease Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Vasodilators for Heart Disease Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Vasodilators for Heart Disease Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Vasodilators for Heart Disease Market Size by Country
  6. 9.2.1 Asia-Pacific Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Vasodilators for Heart Disease Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Vasodilators for Heart Disease Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Vasodilators for Heart Disease Sales by Country
  2. 10.1.1 South America Vasodilators for Heart Disease Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Vasodilators for Heart Disease Sales by Country (2021-2026)
  4. 10.1.3 South America Vasodilators for Heart Disease Sales Forecast by Country (2027-2032)
  5. 10.2 South America Vasodilators for Heart Disease Market Size by Country
  6. 10.2.1 South America Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Vasodilators for Heart Disease Market Size by Country (2021-2026)
  8. 10.2.3 South America Vasodilators for Heart Disease Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Vasodilators for Heart Disease Sales by Country
  2. 11.1.1 Middle East and Africa Vasodilators for Heart Disease Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Vasodilators for Heart Disease Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Vasodilators for Heart Disease Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Vasodilators for Heart Disease Market Size by Country
  6. 11.2.1 Middle East and Africa Vasodilators for Heart Disease Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Vasodilators for Heart Disease Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Vasodilators for Heart Disease Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Vasodilators for Heart Disease Value Chain Analysis
  2. 12.1.1 Vasodilators for Heart Disease Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Vasodilators for Heart Disease Production Mode & Process
  7. 12.2 Vasodilators for Heart Disease Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Vasodilators for Heart Disease Distributors
  10. 12.2.3 Vasodilators for Heart Disease Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst